growth - The 31.8% revenue growth, recent profitability inflection (470% net income growth)…
Rising interest rates create moderate headwinds through two channels: (1) Higher discount rates compress valuation multiples…
Watch on earnings: NUPLAZID weekly prescription data (TRx and NRx) from IQVIA or Symphony Health tracking services, Medicare Part D coverage decisions and prior authorization requirements for dementia-related psychosis indication, Clinical trial enrollment rates and data readout timelines for Phase 3 programs.
One Sentence Summary:
Acadia Pharmaceuticals: the story is balanced — nuplazid prescription volume trends and market share in pdp and drp indications.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.